Shineco is a small Delaware-incorporated, Nasdaq-listed holding company that operates a collection of businesses in China through recently acquired subsidiaries. Shineco's largest segment is rapid diagnostic test kits and medical devices, produced and sold through its 51%-owned subsidiary Biowin, which sells to hospitals, distributors, and international buyers across Europe and Southeast Asia. Its second segment, run through its 71.42%-owned subsidiary Wintus, produces and processes silk fabrics and trades fresh fruit imported from Southeast Asia for distribution to Chinese supermarkets. Shineco also recently opened a single health-oriented restaurant in Fuzhou targeting customers with metabolic health issues, with plans to expand into a chain, though this remains early-stage. Shineco has grown primarily through acquisitions, buying controlling stakes in health and agriculture businesses, and has shifted its business mix substantially over the past two years after fully divesting its legacy VIE-based operations, which included specialty textiles, organic produce, and freight forwarding. The company's business model is straightforward — selling physical goods in China and internationally — but the portfolio is loosely connected operationally, gross margins are thin, and the company has been persistently loss-making, relying on external financing to fund operations and acquisitions.